Oyster Point Pharma, Inc. Common Stock
OYST
OYST was delisted on the 30th of December, 2022.
72 hedge funds and large institutions have $246M invested in Oyster Point Pharma, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 21 closing their positions.
329% more call options, than puts
Call options by funds: $60K | Put options by funds: $14K
10% less funds holding
Funds holding: 80 → 72 (-8)
20% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 20
35% less capital invested
Capital invested by funds: $379M → $246M (-$133M)
38% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 21
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Telemark Asset Management
Boston,
Massachusetts
|
+$9.37M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$8.14M |
| 3 |
Barclays
London,
United Kingdom
|
+$1.25M |
| 4 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$993K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$648K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$3.9M |
| 2 |
SCM
Sio Capital Management
New York
|
-$3.32M |
| 3 |
Millennium Management
New York
|
-$2.19M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$1.69M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.57M |
OYST Hedge Fund Activity: Q1 2022 in Review
72 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Oyster Point Pharma, Inc. Common Stock (OYST) for Q1 2022, worth a combined $246M — down 35% from $379M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of OYST and 13 opened new positions — a net loss of 8 holders — while 20 trimmed existing stakes and 16 added.
The largest buyer was Telemark Asset Management, opening a new position worth an estimated $9.37M. The largest seller was First Manhattan, cutting an estimated $3.9M.
- 72 institutional investors held Oyster Point Pharma, Inc. Common Stock (OYST) as of Q1 2022, down from 80 in Q4 2021.
- Funds reported $246M of Oyster Point Pharma, Inc. Common Stock stock for Q1 2022, down 35% quarter-over-quarter.
- 13 funds opened new Oyster Point Pharma, Inc. Common Stock positions in Q1 2022 and 21 closed out, a net change of -8 holders.
- The largest Oyster Point Pharma, Inc. Common Stock buyer in Q1 2022 was Telemark Asset Management, an estimated $9.37M added.
- The largest Oyster Point Pharma, Inc. Common Stock seller in Q1 2022 was First Manhattan, an estimated $3.9M sold.
Based on aggregated 13F filings for Q1 2022.